Divalproex Sodium
Product Images NDC 68151-1164

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68151-1164). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl681511164)

Label for Divalproex Sodium Delayed-Release 125 mg tablet showing manufacture details including manufacturer code, expiration date (11/14), and product NDC barcode ending in 1164. The label notes prescription use only and the labeler as Carilion Materials Management.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

Bar chart titled Figure 1 comparing percentages of two groups, labeled PBO and DVPX, across two studies named Study 1 (YMRS) and Study 2 (MRS). The chart shows higher percentages for DVPX (60% and 58%) compared to PBO (26% and 29%) in both studies, with percentage values displayed above each bar.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A cumulative distribution curve showing the percent reduction in CPS rate for patients treated with Divalproex Sodium (DVPX) versus placebo. The y-axis represents percentage reduction in CPS rate from -100% to 100%, with improvement increasing upward and worsening downward. The x-axis shows the percentage of patients, from 100% to 0%. The solid line represents DVPX and the dashed line represents placebo.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A cumulative percentage graph showing the percent reduction in CPS (clinical parameter) rate for Divalproex Sodium patients at high and low doses. The y-axis measures percent reduction in CPS rate from -100% to 100%, and the x-axis lists percentage of patients from 0 to 100%. An improvement/worsening scale is indicated vertically, with two curves representing high dose (solid line) and low dose (dashed line) patient responses.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates for Placebo and Divalproex Sodium (labeled as DVPX) across two studies. The vertical axis shows migraine rates, with Placebo bars higher than DVPX bars in both Study 1 and Study 2, indicating lower migraine rates with Divalproex Sodium.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure diagram of divalproex sodium showing its molecular components and arrangement, including sodium ion, carboxylate groups, and hydrocarbon chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.